ArticleJournal of neurosurgery. Case lessons2026
Ivosidenib treatment in IDH-mutant WHO grade 4 astrocytomas: illustrative case.
Article in Journal of neurosurgery. Case lessons, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIsocitrate dehydrogenase (IDH) is a commonly mutated gene in gliomas. Although IDH-mutant WHO grade 4 astrocytomas tend to occur in younger patients and show an improved survival compared to IDH-wildtype, prognosis remains poor and treatment options are limited. Ivosidenib is a small-molecule inhibitor of IDH-1 that has shown promise for treating low-grade IDH-mutant glioma. However, little is known about its efficacy in IDH-mutant WHO grade 4 astrocytoma. OBSERVATIONS: The authors present the case of a 36-year-old male with a IDH-mutant WHO grade 4 astrocytoma. He was originally treated with resection, followed by radiation therapy and temozolomide. At the second recurrence, ivosidenib was started, after lomustine therapy had failed to control the disease. Radiological surveillance showed interval decrease in tumor size starting 2 months after initiation of ivosidenib. The patient remained neurologically intact, and no adverse effects were observed. LESSONS: Here the authors report the effects of the off-label use of ivosidenib. The INDIGO trial published evidence of efficacy in using an IDH inhibitor for low-grade gliomas. The role of these drugs in high-grade IDH-mutant gliomas is currently unknown. Further studies are needed to assess their impact on overall and progression-free survival. https://thejns.org/doi/10.3171/CASE25572.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.